Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt takes Proactive's Stephen Gunnion through the latest findings on IMU-856, a drug candidate initially studied for celiac disease. New data suggests that IMU-856 significantly increases endogenous GLP-1 levels in a dose-dependent manner, which could make it a potential oral treatment for obesity. Vitt detailed the results of a post hoc analysis from a Phase 1b clinical trial, where patients receiving the highest dose of IMU-856 experienced a 250% increase in baseline GLP-1 levels. He also discussed preclinical safety studies in rats, which demonstrated a dose-dependent reduction in weight gain—further supporting the drug's potential in obesity management. The global obesity treatment market is projected to reach $170 billion, with current solutions mainly relying on injectable GLP-1 mimetics. Vitt highlighted that IMU-856’s potential as an oral therapy could offer a new and more convenient option for patients. Stay updated on Immunic Inc’s progress by watching Proactive’s latest interviews. Don’t forget to like this video, subscribe to our channel, and enable notifications for more updates. #ImmunicInc #IMUX #Biotech #Pharmaceuticals #GLP1 #ObesityTreatment #ClinicalTrials #Healthcare #Investing #ProactiveInvestors